Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations review found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://letitiaw603rzh7.bmswiki.com/user